DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.

Phase 3 · 2019

PIONEER 6

Oral semaglutide (Rybelsus). Adults with type 2 diabetes at high cardiovascular risk.

Trial summary

Primary endpoint

First occurrence of CV death, non-fatal MI, or non-fatal stroke.

Result

Non-inferior CV safety vs placebo (HR 0.79, 95% CI 0.57-1.11). 51% reduction in CV mortality (HR 0.49).

Population

Who was studied

Adults with type 2 diabetes at high cardiovascular risk.

Intervention

Oral semaglutide 14 mg daily vs placebo.

Primary endpoint

First occurrence of CV death, non-fatal MI, or non-fatal stroke.

Result

Non-inferior CV safety vs placebo (HR 0.79, 95% CI 0.57-1.11). 51% reduction in CV mortality (HR 0.49).